

CURRICULUM VITAE:

Franklin G. Berger

June 2016

PERSONAL:

Born September 26, 1947, Providence, RI

Married to Josanne Verdery Wilson

HOME ADDRESS:

6709 Sandy Shore Rd.

Columbia, SC 29206

803-787-0059

BUSINESS ADDRESS:

Department of Biological Sciences

Center for Colon Cancer Research

University of South Carolina

Columbia, SC 29208

PH: 803-777-1231

FAX: 803-777-1173

EDUCATION:

1969 B.A. in Biology/Chemistry, State University of New York at Buffalo,
Buffalo, NY.

1974 Ph.D. in Biochemistry, Purdue University, West Lafayette, Indiana.

EMPLOYMENT:

1974-76 Post-doctoral associate in laboratory of J. Calvo, Cornell University, Ithaca, NY.

1976-79 Post-doctoral associate in laboratory of K. Paigen, Roswell Park Memorial
Institute, Buffalo, NY.

1979-82 Cancer Research Scientist II, Roswell Park Memorial Institute,
Buffalo, NY.

1982-85 Cancer Research Scientist III and Assistant Professor of Cell and Molecular
Biology, Roswell Park Memorial Institute, Buffalo, NY.

1985-91 Associate Professor of Biology, University of South Carolina, Columbia, SC.

1987-90 Director, Institute of Biological Research and Technology, University of South Carolina,
Columbia, SC.

1991- Professor, Department of Biological Sciences, University of South Carolina,

Curriculum Vitae: F.G. Berger

Columbia, SC.
1993- George H. Bunch Sr., Professor of Science
1996-2002 Chair, Department of Biological Sciences, University of South Carolina, Columbia, SC.
2002- Director, Center for Colon Cancer Research

SCHOLARSHIPS AND AWARDS:

1975-76 National Institutes of Health Postdoctoral Fellow

1990 Fulbright Fellow, Lund University, Lund, Sweden

1993 George H. Bunch Sr., Professor of Science

1999 Educational Foundation Research Award for Science, Mathematics, and Engineering ,
University of South Carolina

2004 Center of Economic Excellence (in conjunction with Dr. Ken Tew of the Medical
University of South Carolina)

2005 Governor's Award for Excellence in Scientific Research

2006 Mortar Board Excellence in Teaching Award

2009 Outstanding Service Award, South Carolina Gastroenterology Association

2011 Fellow of the American Association for the Advancement of Science

2012 Laurel Award for Innovative Programs, Prevent Cancer Foundation

2013 Breakthrough Leadership in Research Award, University of South Carolina

PATENTS:

U.S. patent 5,648,597 Alpha-1-acid Glycoprotein Transgenic Mice. Co-inventors M.J. Dewey (Univ. of S. Carolina), H. Baumann (Roswell Park Cancer Inst.)

PEER-REVIEWED PUBLICATIONS:

- (1.) **Berger, F.G.** and K.M. Herrmann. 1975. Tryptophan synthetase $\alpha(5.7S)$, novel species formed within *Escherichia coli*. *J. Bacteriol.* **124**:800-809.
- (2.) **Berger, F.G.**, K. Paigen, and M.H. Meisler. 1978. Regulation of the rate of β -galactosidase synthesis by the *Bgs* and *Bgt* loci in the mouse. *J. Biol. Chem.* **253**:5280-5282.
- (3.) **Berger, F.G.** and A.J. Lusic. 1978. Relationship between genetic variation in thermal stability and electrophoretic mobility for mouse β -galactosidase. *Biochem. Genet.* **16**:1007-1014.
- (4.) **Berger, F.G.**, G.A.M. Breen, and K. Paigen. 1979. Genetic determination of the developmental program for mouse liver β -galactosidase: involvement of sites proximate to and distant from the

- structural gene. *Genetics* **92**:1187-1203.
- (5.) **Berger, F.G.** and K. Paigen. 1979. *Cis*-active control of mouse β -galactosidase biosynthesis by a systemic regulatory locus. *Nature* **282**:314-316.
 - (6.) **Berger, F.G.**, K. Gross, and G. Watson. 1981. Isolation and characterization of a DNA sequence complementary to an androgen-inducible messenger RNA from mouse kidney. *J. Biol. Chem.* **256**:7006-7013.
 - (7.) **Berger, F.G.** and P. Szoka. 1981. Biosynthesis of the major urinary proteins in mouse liver: A biochemical genetic study. *Biochem. Genet.* **19**:1261-1273.
 - (8.) Elliot, R.W. and **F.G. Berger**. 1983. DNA sequence polymorphism in an androgen-regulated gene is associated with alteration in the encoded family of RNAs. *Proc. Natl. Acad. Sci. USA* **80**:501-504.
 - (9.) **Berger, F.G.** 1983. Studies on genetic variation in major urinary protein synthesis in mouse liver. *Biochem. Genet.* **21**:15-23.
 - (10.) Baumann, H., W.A. Held, and **F.G. Berger**. 1984. The acute phase response of mouse liver: genetic analysis of the major acute phase reactants. *J. Biol. Chem.* **259**:566-573.
 - (11.) **Berger, F.G.**, P. Szymanski, E. Read, and G. Watson. 1984. Ornithine decarboxylase mRNAs of mouse kidney. *J. Biol. Chem.* **259**:7941-7946.
 - (12.) **Berger, F.G.** and H. Baumann. 1985. An evolutionary switch in tissue-specific gene expression: Abundant expression of α_1 -antitrypsin in the kidney of a wild mouse species. *J. Biol. Chem.* **260**:1160-1165.
 - (13.) Berger, S.H., C.-H. Jenh, L.F. Johnson, and **F.G. Berger**. 1985. Thymidylate synthase overproduction and gene amplification in a human cell line. *Mol. Pharmacol.* **28**:461-467.
 - (14.) Baumann, H. and **F.G. Berger**. 1985. Genetics and evolution of the acute phase proteins in mice. *Mol. Gen. Genet.* **201**:505-512.
 - (15.) **Berger, F.G.**, D. Loose, H. Meisner, and G. Watson. 1986. Androgen induction of messenger RNA concentrations in mouse kidney is post-transcriptional. *Biochemistry.* **25**:1170-1175.
 - (16.) **Berger, F.G.** and C.W. Porter. 1986. Putrescine does not mediate the androgen-response in mouse kidney. *Biochem. Biophys. Res. Commun.* **138**:771-777.
 - (17.) Nadeau, J.H., **F.G. Berger**, K.A. Kelley, P.M. Pitha, C.L. Sidman, and N. Worrall. 1986. Rearrangement of genes located on homologous chromosomal segments in mouse and man: the location of genes for α - and β -interferon, α_1 -acid glycoprotein-1 and -2, and amino-levulinic acid dehydratase on mouse chromosome 4. *Genetics* **104**:1239-1255.
 - (18.) Porter, C.W., **F.G. Berger**, A.E. Pegg, B. Ganis, and R.J. Bergeron. 1987. Regulation of ornithine decarboxylase activity by spermidine and the spermidine analog, N¹, N⁸-BIS(ethyl)spermidine. *Biochem. J.* **242**:433-440.
 - (19.) Clark, J.L., S.H. Berger., A. Mittelman, and **F.G. Berger**. 1987. Thymidylate synthase gene amplification in a colon tumor resistant to fluoropyrimidine chemotherapy. *Cancer Treatment Rep.* **71**:262-265.
 - (20.) Tseng-Crank, J. and **F.G. Berger**. 1987. Evolution of steroid-inducible *RP2* mRNA expression in mouse kidney. *Genetics* **116**:593-599.
 - (21.) Latimer, J.J., **F.G. Berger**, and H. Baumann. 1987. Developmental expression, cellular localization, and testosterone regulation of α_1 -antitrypsin expression in *Mus caroli* kidney. *J. Biol. Chem.* **262**:12641-12646.
 - (22.) Barbour, K.W., S.H. **Berger, F.G. Berger**, and E.A. Thompson, Jr. 1988. Glucocorticoid regulation of the genes encoding thymidine kinase, thymidylate synthase, and ornithine decarboxylase in P1798 cells. *Mol. Endocrinol.* **2**:78-84.

Curriculum Vitae: F.G. Berger

- (23.) Tseng-Crank, J., C. Schonfeld, and **F.G. Berger**. 1988. Evolution of androgen-regulated mRNA expression in mouse kidney. *Mol. Biol. Evol.* **5**:442-454.
- (24.) Berger, S.H. and **F.G. Berger**. 1988. Thymidylate synthase as a determinant of 5-fluoro-2'-deoxyuridine response in human colonic tumor cells. *Mol. Pharmacol.* **34**:474-479.
- (25.) Berger, S.H., K.W. Barbour, and **F.G. Berger**. 1988. A naturally-occurring variation in thymidylate synthase structure is associated with a reduced response to 5-fluoro-2'-deoxyuridine in a human colonic tumor cell line. *Mol. Pharmacol.* **34**:480-484.
- (26.) Rheaume, C., J.J. Latimer, H. Baumann, and **F.G. Berger**. 1988. Tissue and species-specific regulation of murine α_1 -antitrypsin gene transcription. *J. Biol. Chem.* **263**:15118-15121.
- (27.) Berger, S.H., S.T. Davis, K.W. Barbour, and **F.G. Berger**. 1988. The role of thymidylate synthase in the response to fluoropyrimidine-folinic acid combinations. *Adv. Expl. Med. Biol.* **244**:59-69.
- (28.) **Berger, F.G.** and G. Watson. 1989. Androgen-regulated gene expression. *Ann. Rev. Physiol.* **51**:51-67.
- (29.) Rheaume, C., K.W. Barbour, J. Tseng-Crank, and **F.G. Berger**. 1989. Molecular genetics of androgen-inducible *RP2* gene transcription in the mouse kidney. *Mol. Cell. Biol.* **9**:477-483.
- (30.) Rheaume, C., C. Schonfeld, C. Porter, and **F.G. Berger**. 1989. Evolution of androgen-regulated ornithine decarboxylase expression in mouse kidney. *Mol. Endocrinol.* **3**:1243-1251.
- (31.) **Berger, F.G.** 1989. Assignment of a gene encoding ornithine decarboxylase to the proximal region of mouse chromosome 12 in the mouse. *Biochem. Genet.* **27**:745-753.
- (32.) Nadeau, J.H., **F.G. Berger**, D.R. Cox, *et al.* 1989. A family of type I keratin genes and the homeobox-2 gene complex are closely linked to the Rex locus on chromosome 11. *Genomics* **5**:454-462.
- (33.) Latimer, J.J., **F.G. Berger**, and H. Baumann. 1990. Highly conserved upstream regions of the α_1 -antitrypsin gene in two mouse species govern liver-specific expression by different mechanisms. *Mol. Cell. Biol.* **10**:760-769.
- (34.) Dewey, M.J., C. Rheaume, **F.G. Berger**, and H. Baumann. 1990. Inducible and tissue-specific expression of rat alpha-1-acid glycoprotein in transgenic mice. *J. Immunol.* **144**:4392-4398.
- (35.) Barbour, K.W., S.H. Berger, and **F.G. Berger**. 1990. Single amino acid substitution defines a naturally-occurring genetic variant of human thymidylate synthase. *Mol. Pharmacol.* **37**:515-518.
- (36.) Rhee, M., D. D. Dimaculangan, and **F.G. Berger**. 1991. Androgen modulation of DNA binding factors in the mouse kidney. *Mol. Endocrinol.* **5**:564-572.
- (37.) Johannes, G. and **F.G. Berger**. 1991. An evolutionarily-derived reduction in the translational efficiency of ornithine decarboxylase mRNA in mice. *Life Chemistry Reports* **9**:19-28.
- (38.) Chaudhuri, A., K. Barbour, and **F.G. Berger**. 1991. Evolution of messenger RNA structure and regulation in the genus *Mus*: The androgen-inducible *RP2* mRNAs. *Mol. Biol. Evol.* **8**:641-653.
- (39.) Mackiewicz, A., M.J. Dewey, **F.G. Berger**, and H. Baumann. 1991. Acute phase mediated change in glycosylation of rat α_1 -acid glycoprotein in transgenic mice. *Glycobiology* **1**:265-269.
- (40.) Mackiewicz, A., A. Pos, M. Van der Stelt, S.H. Yap, M. Kapcinska, M. Laciak, M. Dewey, **F.G. Berger**, H. Baumann, I. Kushner, and W. van Dijk. 1991. Regulation of glycosylation of acute phase proteins by cytokines. In: Affinity electrophoresis: Principles and Application. Breborowicz, J. and Mackiewicz, A. (eds.) CRC Press, Inc., pp 135-153.
- (41.) Johannes, G.J. and **F.G. Berger**. 1992. Alterations in mRNA translation as a mechanism for the modification of enzyme synthesis during evolution: the ornithine decarboxylase model. *J. Biol. Chem.* **267**:10108-10115.
- (42.) Kass, D. H., F. G. Berger, W. D. Dawson. 1992. The evolution of coexisting highly divergent

- LINE-1 subfamilies within the rodent genus *Peromyscus*. *J. Mol. Evol.* **35**:472-485.
- (43.) Barbour, K.W., D.K. Hoganson, S.H. Berger, and **F.G. Berger**. 1992. A naturally-occurring tyrosine to histidine replacement at residue 33 of human thymidylate synthase confers resistance to 5-fluoro-2'-deoxyuridine in mammalian and bacterial cells. *Mol. Pharmacol.* **42**:242-248.
- (44.) Hughey, C.T., K.W. Barbour, **F.G. Berger**, and S.H. Berger. 1993. Genetic variation in thymidylate synthase confers resistance to 5-fluorodeoxyuridine. *Adv. Expl. Med. Biol.* **339**:67-76.
- (45.) Johannes, G.J. and **F.G. Berger**. 1993. Domains within the mammalian ornithine decarboxylase messenger RNA have evolved independently and episodically. *J. Mol. Evol.* **36**:555-567.
- (46.) Hughey, C.T., K.W. Barbour, **F.G. Berger**, and S.H. Berger. 1993. Functional effects of a naturally occurring amino acid substitution in human thymidylate synthase. *Mol. Pharmacol.* **44**:316-323.
- (47.) Rheume, C., R.L. Goodwin, J.J. Latimer, H. Baumann, and **F.G. Berger**. 1994. Evolution of murine α_1 -proteinase inhibitors: gene amplification and reactive center divergence. *J. Mol. Evol.* **38**:121-131.
- (48.) Pajovic, S.P., V.E. Jones, K.R. Prowse, **F.G. Berger**, and H. Baumann. 1994. Species-specific changes in regulatory elements of mouse haptoglobin genes. *J. Biol. Chem.* **269**:2215-2224.
- (49.) Asadi, F., D.D. Dimaculangan, and **F.G. Berger**. 1994. Androgen regulation of gene expression in primary epithelial cells of the mouse kidney. *Endocrinology* **134**:1179-1187.
- (50.) Reilly, R.T., K.W. Barbour, R.B. Dunlap, and **F.G. Berger**. 1995. Biphasic binding of 5-fluoro-2'-deoxyuridylate to human thymidylate synthase. *Mol. Pharmacol.* **48**:72-79.
- (51.) **Berger, F.G.** and G. Watson. 1996. Measurement of steroid receptor binding to DNA. in *Endocrine Methods*. Thomas, J.A., ed., Academic Press, pp. 89-100.
- (52.) Goodwin, R.L., H. Baumann, and **F.G. Berger**. 1996. Patterns of divergence during evolution of α_1 -proteinase inhibitors in mammals. *Mol. Biol. Evol.* **13**:346-358.
- (53.) Goodwin, R.L., Barbour, K.W., and **F.G. Berger**. 1997. Expression of the α_1 -proteinase inhibitor gene family during evolution of the genus *Mus*. *Mol. Biol. Evol.* **14**:420-428.
- (54.) Reilly, R.T., A. Forsthoefel, and **F.G. Berger**. 1997. Functional effects of amino acid substitutions at residue 33 of human thymidylate synthase. *Arch. Biochem. Biophys.* **342**:338-343.
- (55.) Singh, N., K. Barbour, and **F.G. Berger**. 1998. Evolution of transcriptional regulatory elements within the promoter of a mammalian gene. *Mol. Biol. Evol.* **15**:312-325.
- (56.) Singh, N., and **F.G. Berger**. 1998. Nucleotide substitutions within the regulatory elements of a mammalian promoter confer differential binding of transcription factors and alter gene expression during evolution. *J. Mol. Evol.* **46**:639-648.
- (57.) Libert, C., T. Hocheplid, **F.G. Berger**, H. Baumann, W. Fiers, and P. Brouckaert. 1998. High-level constitutive expression of α_1 -acid glycoprotein and lack of protection against tumor necrosis factor-induced lethal shock in transgenic mice. *Transgenic Res.* **7**:429-435.
- (58.) Kitchens, M.E., A.M. Forsthoefel, Z. Rafique, H.T. Spencer, and **F.G. Berger**. 1999. Ligand-mediated induction of thymidylate synthase occurs by enzyme stabilization. Implications for autoregulation of translation. *J. Biol. Chem.* **274**:12544-12547.
- (59.) Persson, K., O. Heby, and **F.G. Berger**. 1999. The functional intronless S-adenosylmethionine decarboxylase gene of the mouse (*Amd-2*) is linked to the ornithine decarboxylase gene (*Odc*) on chromosome 12, and is present in distantly-related species of the genus *Mus*. *Mammal. Genome* **10**:784-788.
- (60.) Kitchens, M.E., A.M. Forsthoefel, K.W. Barbour, H.T. Spencer, and **F.G. Berger**. 1999.

Mechanisms of acquired resistance to thymidylate synthase inhibitors: the role of enzyme stability. *Mol. Pharmacol.* **56**:1063-1070.

- (61.) Fantz, C., D. Shaw, W. Jennings, A.M. Forsthoefel, M.E. Kitchens, J. Phan, W. Minor, L. Lebioda, **F.G. Berger**, and H.T. Spencer. 2000. Drug-resistant variants of *Escherichia coli* thymidylate synthase: Effects of substitutions at Pro254. *Mol. Pharmacol.* **57**:359-366.
- (62.) Hochepped, T., W. Van Molle, **F.G. Berger**, H. Baumann, and C. Libert. 2000. Involvement of the acute phase protein α_1 -acid glycoprotein in nonspecific resistance to a lethal gram-negative infection. *J. Biol. Chem.* **275**:14903-14909.
- (63.) Shaw, D., **F.G. Berger**, and H.T. Spencer. 2001. Retroviral expression of *Escherichia coli* thymidylate synthase cDNA confers high-level antifolate resistance to hematopoietic cells. *Human Gene Therapy* **12**:51-60.
- (64.) Barker, C., K.W. Barbour, **F.G. Berger**, and S.L. Hajduk. 2001. Activity of human trypanosome lytic factor in mice. *Mol. Biochem. Parasitol.* **117**:129-136.
- (65.) Barbour, K.W., C. Davis, A. White, H. Baumann, and **F.G. Berger**. 2001. Haptoglobin, inflammation, and tumorigenesis in the MIN mouse. *Redox Report* **6**:366-368.
- (66.) Wang, Y., E. Kinzie, **F.G. Berger**, S.-K. Lim, and H. Baumann. 2001. Haptoglobin, the inflammation-inducible plasma protein. *Redox Report* **6**:379-385.
- (67.) Barbour, K.W., R.L. Goodwin, F. Guillonneau, Y. Wang, H. Baumann, and **F.G. Berger**. 2002. Functional diversity among members of the murine α_1 -proteinase inhibitor family. *Mol. Biol. Evol.* **19**:718-727.
- (68.) Hochepped, T., A. Wullaert, **F.G. Berger**, H. Baumann, P. Brouckaert, L. Steidler, L. and C. Libert. 2002. Overexpression of alpha-1-acid glycoprotein in transgenic mice leads to sensitization to acute colitis. *Gut* **51**: 398-404.
- (69.) Tucker, J.M., C. Davis, M.E. Kitchens, M.A. Bunni, D.G. Priest, H.T. Spencer, and **F.G. Berger**. 2002. Response to 5-fluorouracil chemotherapy is modified by dietary folic acid deficiency in *Apc^{Min/+}* mice. *Cancer Letters* **187**:153-162.
- (70.) Barbour, K.W., F.-S. Wang, C. Brannan, T.R. Flotte, H. Baumann, and **F.G. Berger**. 2002. The murine α_1 -proteinase inhibitor gene family: Polymorphism, chromosomal location, and structure. *Genomics* **80**:515-522.
- (71.) Tolosano, E., S. Fagoonee, E. Hirsch, **F.G. Berger**, H. Baumann, L. Silengo, and F. Altruda. 2002. Enhanced splenomegaly and severe liver inflammation in haptoglobin/hemopexin double null mice after acute hemolysis. *Blood* **100**:4201-4208.
- (72.) Yang, F., D. J. Haile, **F.G. Berger**, D.C. Herbert, E. Van Beveren, and A.J. Ghio. 2003. Haptoglobin reduces lung injury associated with exposure to blood. *Amer. J. Physiol.* **284**:L402-L409.
- (73.) Hochepped, T., **F.G. Berger**, H. Baumann, and C. Libert. 2003. Alpha-1-acid glycoprotein: an acute phase protein with inflammatory and immunomodulating properties. *Cytokine Growth Factor Rev.* **14**:25-34.
- (74.) Berger, S.H., **F.G. Berger**, and L. Lebioda. 2004. Effects of ligand binding and conformational switching on stability of human thymidylate synthase. *Biochim. Biophys. Acta* **1696**:15-22.
- (75.) Forsthoefel, A.M., M. Peña, Y.Y. Xing, Z. Rafique, and **F.G. Berger**. 2004. Structural determinants for the intracellular degradation of human thymidylate synthase. *Biochemistry* **43**:1972-1979.
- (76.) **Berger, F.G.** 2004. Interleukin-6: a susceptibility factor that may be involved in racial and ethnic disparities in breast cancer mortality. *Breast Cancer Res. Treat.* **88**:281-285.
[This review article was highlighted in the December 10 issue of *BreastCancer Net News*.]

- (77.) Murphy, J.T., J.M. Tucker, C. Davis, and **F.G. Berger**. 2004. Raltitrexed increases tumorigenesis as a single agent yet exhibits anti-tumor synergy with 5-fluorouracil in *Apc^{Min/+}* mice. *Cancer Biol. Therapy* **3**:1169-1176.
- (78.) Arredouani, M.S., A. Kasran, J.A. Vanoirbeek, **F.G. Berger**, H. Baumann, and J.L. Ceuppens. 2005. Haptoglobin dampens endotoxin-induced inflammatory effects both in vitro and in vivo. *Immunology* **114**:263-271.
- (79.) Mehl, K.A., J.M. Davis, J.M. Clermens, **F.G. Berger**, M.M. Pena, and J.A. Carson. 2005. Decreased intestinal polyp multiplicity is related to exercise mode and gender in *Apc^{Min/+}* mice. *J. Appl. Physiol.* **98**:2219-2225.
- (80.) Miller-Lotan, R., Y. Herskowitz, S. Kalet-Litman, F. Nakhoul, D. Aronson, R. Zoabi, R. Asaf, O. Ben-Izhak, E. Sabo, S.K. Lim, H. Baumann, **F.G. Berger**, and A.P. Levy. 2005. Increased renal hypertrophy in diabetic mice genetically modified at the haptoglobin locus. *Diabetes Metab. Res. Rev.* **21**:332-337.
- (81.) Tucker, J.M., J.T. Murphy, N. Kisiel, P. Diegelman, K.W. Barbour, C. Davis, L. Alhonen, J. Jänne, D.L. Kramer, C.W. Porter, and **F.G. Berger**. 2005. Potent modulation of intestinal tumorigenesis by the polyamine catabolic enzyme spermidine/spermine *N*¹-acetyltransferase-1 in *Apc^{Min/+}* mice. *Cancer Research* **65**:5390-5398.
- (82.) Mehl, K.A., J.M. Davis, **F.G. Berger**, and J.A. Carson. 2005. Cancer cachexia is related to systemic inflammation in the *Apc^{Min/+}* mouse. *J. Appl. Physiol.* **99**:2379-2387.
- (83.) Peña, M., Y.Y. Xing, S. Koli, and **F.G. Berger**. 2006. Role of N-terminal residues in ubiquitin-independent degradation of human thymidylate synthase. *Biochem. J.* **394**:355-363.
- (84.) You, S., M. Ohmori, M.M. Peña, B. Nassri, J. Quiton, Z.A. Al-Assad, L. Liu, P.A. Wood, S.H. Berger, Z. Liu, M.D. Wyatt, R.L. Price, **F.G. Berger**, and W.J. Hrushesky. 2006. Developmental abnormalities in multiple proliferative tissues of *Apc^{Min/+}* mice. *Int. J. Exp. Path.* **87**:227-236.
- (85.) **Berger, F.G.** and S.H. Berger. 2006. Thymidylate synthase as a chemotherapeutic drug target: Where are we after fifty years? *Cancer Biol. Therapy* **5**:1238-1241.
- (86.) Blum S., R. Asaf, J. Guetta, R. Miller-Lotan, R. Asleh, R. Kremer, N.S. Levy, **F.G. Berger**, D. Aronson, X. Fu, R. Zhang, S.L. Hazen, and A.P. Levy. 2007. Haptoglobin genotype determines myocardial infarct size in diabetic mice. *J. Am. Coll. Cardiol.* **49**: 82-87.
- (87.) **Berger, F.G.**, D.L. Kramer, and C.W. Porter. 2007. Polyamine metabolism and tumorigenesis in the *Apc^{Min/+}* mouse. *Biochem. Soc. Trans.* **35**:336-339.
- (88.) Barbour, K.W. and **F.G. Berger**. 2008. Cell death in response to antimetabolites directed at thymidylate synthase. *Cancer Chemother. Pharmacol.* **61**:189-201.
- (89.) Baltgalvis K.A., **F.G. Berger**, M.M. Pena, J.M. Davis, S.J. Muga, and J.A. Carson. 2008. Interleukin-6 and cachexia in *Apc^{Min/+}* mice. *Am. J. Physiol. Regul. Integr. Comp. Physiol.* **294**:R393-401.
- (90.) Kwon, I.K., P.V. Schoenlein, J. Delk, K. Liu, M. Thangaraju, N. Dulin, V. Ganapathy, **F.G. Berger**, and D.D. Browning. 2008. Expression of PKG in metastatic colon carcinoma cells blocks tumor angiogenesis. *Cancer* **112**:1462-1470.
- (91.) Baltgalvis K.A., **F.G. Berger**, M.M. Pena, J.M. Davis, and J.A. Carson. 2008. The effect of exercise on biological pathways in *Apc^{Min/+}* mouse intestinal polyps. *J. Appl. Physiol.* **104**:1137-1143.
- (92.) Misra, S., L.M. Obeid, Y.A. Hannun, S. Minamisawa, **F.G. Berger**, R.R. Markwald, B.P. Toole, and S. Ghatak. 2008. Hyaluronan constitutively regulates activation of COX-2-mediated cell survival activity in intestinal epithelial and colon carcinoma cells. *J. Biol. Chem.*

- 283:14335-14344.
- (93.) Huntoon, K.M., Y. Wang, C.A. Eppolito, K.W. Barbour, **F.G. Berger**, P. Shrikant, and H. Baumann. 2008. The acute phase protein haptoglobin regulates host immunity. *J. Leukoc. Biol.* **84**:170-181.
- (94.) Ghatak, S., V.C. Hascall, **F.G. Berger**, M.M. Peña, M.M., C. Davis, E. Jabari, X. He, J.S. Norris, Y. Dang, R.R. Markwald, and S. Misra. 2008. Tissue-specific shRNA delivery: a novel approach for gene therapy in cancer. *Connect. Tissue Res.* **49**:265-269.
- (95.) Misra S, V.C. Hascall, **F.G. Berger**, R.R. Markwald, and S. Ghatak. 2008. Hyaluronan, CD44, and cyclooxygenase-2 in colon cancer. *Connect Tissue Res.* **49**:219-224.
- (96.) Thangaraju, M., G. Cresci, S. Itagaki, J. Mellinger, D.D. Browning, **F.G. Berger**, P.D. Prasad, and V. Ganapathy. 2008. Sodium-coupled transport of the short chain fatty acid butyrate by SLC5A8 and its relevance to colon cancer. *J Gastrointes. Surg.* **12**:1773-1781.
- (97.) Wood, P.A., X. Yang, A. Taber, E.Y. Oh, C. Ansell, S.E. Ayers, Z. Al-Assaad, K. Carnevale, **F.G. Berger**, M.M. Pena, and W.J. Hrushesky. 2008. Period 2 mutation accelerates ApcMin/+ tumorigenesis. *Mol. Cancer Res.* **6**:1786-1793.
- (98.) Baltgalvis, K.A., **F.G. Berger**, M.M. Peña, J.M. Davis, J.P. White, and J.A. Carson. 2009. Muscle wasting and interleukin-6-induced atrogen-I expression in the cachectic Apc(Min/+) mouse. *Eur. J. Physiol.* **457**:989-1001.
- (99.) Yang, X., P.A. Wood, C.M. Ansell, M. Ohmori, E.Y. Oh, Y. Xiong, **F.G. Berger**, M.M. Peña, and W.J. Hrushesky. 2009. beta-Catenin induces {beta}-TrCP-mediated PER2 degradation altering circadian clock gene expression in intestinal mucosa of ApcMin/+ mice. *J. Biochem.* **145**:289-297.
- (100.) Watanabe J. V. Grijalva, S. Hama, K. Barbour, **F. Berger**, M. Navab, A.M. Fogelman, and S.T. Reddy. 2009. Hemoglobin and its scavenger protein haptoglobin associate with apoA-1 containing particles and influence the inflammatory properties and function of high density lipoprotein. *J. Biol Chem.* **284**:18292-18301.
- (101.) Baltgalvis K.A., **F.G. Berger**, M.M. Peña, J.M. Davis, and J.A. Carson. 2009. The interaction of a high-fat diet and regular moderate intensity exercise on intestinal polyp development in ApcMin/+ mice. *Cancer Prev. Res.* **2**:641-649.
- (102.) Peña, M.M., S. Melo, Y.-Y. Xing, K. White, K.W. Barbour, and **F.G. Berger**. 2009. The intrinsically disordered N-terminal domain of thymidylate synthase targets the enzyme to the ubiquitin-independent proteasomal degradation pathway. *J. Biol. Chem.* **284**:31597-31607.
- (103.) Huang, X., L.M. Gibson, B.J. Bell, L.L. Lovelace, M.M.O. Peña, **F.G. Berger**, S.H. Berger, and L. Lebioda. 2010. Replacement of Val3 in human thymidylate synthase affects its kinetic properties and intracellular stability. *Biochemistry* **29**:2475-2482.
- (104.) Baltgalvis, K.A., **F.G. Berger**, M.M. Peña, J.M. Davis, J.P. White, and J.A. Carson. 2010. Activity level, apoptosis, and the development of cachexia in ApcMin/+ mice. *J. Appl. Physiol.* **109**:1155-1161.
- (105.) Melo, S.P., A. Yoshida, and **F.G. Berger**. 2010. Functional dissection of the N-terminal degron of human thymidylate synthase. *Biochem. J.* **432**:217-226.
- (106.) Zhang, X., G. Wan, S. Mlotshwa, V. Vance, **F.G. Berger**, H. Chen, and X. Lu. 2010. Oncogenic Wip1 phosphatase is inhibited by miR-16 in the DNA damage signaling pathway. *Cancer Res.* **70**:7176-86.
- (107.) Zhang, X., G. Wan, **F.G. Berger**, X. He, and X. Lu. 2011. The ATM kinase induces microRNA biogenesis in the DNA damage response. *Mol. Cell* **41**:371-383.
- (108.) Zhang, X., **F.G. Berger**, J. Yang, and X. Lu. 2011. USP4 inhibits p53 through

- deubiquitinating and stabilizing ARF-BP1. *EMBO J.* **30**:2177-2189.
- (109.) Davis, C., R. Price, G. Acharya, T. Baudino, T. Borg, **F.G. Berger**, and M.M. Peña. 2011. Hematopoietic derived cell infiltration of the intestinal tumor microenvironment in ApcMin/+ mice. *Microsc. Microanal.* **17**:528-539.
- (110.) Melo, S.P., K.W. Barbour, and **F.G. Berger**. 2011. Cooperation between an intrinsically disordered region and a helical segment is required for ubiquitin-independent degradation by the proteasome. *J. Biol. Chem.* **286**:36559–36567.
- (111.) Lo, P.K., D. Kanojia, X. Liu, U.P. Singh, **F.G. Berger**, Q. Wang, and H. Chen. 2012. CD49f and CD61 identify Her2/neu-induced mammary tumor-initiating cells that are potentially derived from luminal progenitors and maintained by the integrin-TGF β signaling. *Oncogene* **31**:2614-2626.
- (112.) Brandt, H.M., H.L. Dolinger, P.A. Sharpe, J.W. Hardin, and **F.G. Berger**. 2012. The relationship between colorectal cancer awareness and knowledge with colorectal cancer screening. *Colorectal Cancer* **1**:383-396.
- (113.) McClellan, J.L., J.M. Davis, J.L. Steiner, R.T. Enos, S.H. Jung, J.A. Carson, M.M. Peña, K.A. Carnevale, **F.G. Berger**, and E.A. Murphy. 2012. Linking tumor associated macrophages, inflammation, and intestinal tumorigenesis: Role of MCP-1. *Am. J. Physiol. Gastrointest. Liver Physiol.* **303**:G1087-G1095.
- (114.) Lo P.K., J.S. Lee, H. Chen, D. Reisman, **F.G. Berger**, and S. Sukumar. 2012. Cytoplasmic mislocalization of overexpressed FOXF1 is associated with the malignancy and metastasis of colorectal adenocarcinomas. *Exp. Mol. Pathol.* **94**:262-269.
- (115.) Barbour, K.W., Y.-Y. Xing, E.A. Peña, and **F.G. Berger**. 2013. Characterization of the bipartite degron that regulates ubiquitin-independent degradation of thymidylate synthase. *Bioscience Rep.* **33**:165-173.
- (116.) Wallace, K., E.G. Hill, D.N. Lewin, G. Williamson, S. Oppenheimer, M.E. Ford, M.J. Wargovich, **F.G. Berger**, S.W. Bolick, M.B. Thomas, and A.J. Alberg. 2013. Racial disparities in advanced stage colorectal cancer survival. *Cancer Causes Control.* **24**:463-471.
- (117.) Huntoon, K.M., L. Russell, E. Tracya, K.W. Barbour, Q. Li, P.A. Shrikant, **F.G. Berger**, L.A. Garrett-Sinhab, and H. Baumann. 2013. A unique form of haptoglobin produced by murine hematopoietic cells supports B-cell survival, differentiation and immune response. *Mol. Immunol.* **55**:345-354.
- (118.) **Berger, F.G.** 2014. Patient navigation and cancer disparities in the era of personalized medicine. *Colorectal Cancer* **3**:109-112.
- (119.) van der Steen, A., A.B. Knudsen, F. van Hees, G. Walter, **F.G. Berger**, V. Daguise, K.M. Kuntz, A.G. Zauber, M.V. Ballegooijen, and I. Lansdorp-Vogelaar. 2015. Optimal colorectal cancer screening in states' low-income, uninsured populations. The case for South Carolina. *Health Serv. Res.* **50**:768-789.
- (120.) Ozer, U., K.W. Barbour, S.A. Clinton, and **F.G. Berger**. 2015. Oxidative stress and response to thymidylate synthase-targeted anti-metabolites. *Mol. Pharmacol.* **88**:970-981.
- (121.) **Berger, F.G.** and C.W. Hansen. 2015. The Medicare loophole: cost-sharing for screening colonoscopy. *Colorectal Cancer* **4**: 221-223
- (122.) Wallace, K., H.M. Brandt, J.D. Bearden, B.F. Blankenship, R. Caldwell, J. Dunn, P. Hegedus, B.J. Hoffman, C.H. Marsh, W.H. Marsh, C.L. Melvin, M.E. Seabrook, R.E. Sterba, M.L. Stinson, A. Thibault, **F.G. Berger**, and A.J. Alberg. 2016. Race and prevalence of large bowel polyps among the low-income and uninsured in South Carolina. *Dig. Dis. Sci.* **61**:265-272.

SELECTED ABSTRACTS AND OTHER RELEVANT PUBLICATIONS:

- (1.) **Berger, F.G.** and P.R. Szoka. 1980. Androgen Induction of Major Urinary Protein Synthesis in Mouse Liver: Biochemical and Genetic Analysis. *Fed. Proc.* **39**:1746.
- (2.) **Berger, F.G.** 1982. Genetic Regulation of Major Urinary Protein Synthesis in Mouse Liver. *Fed. Proc.* **41**:632.
- (3.) **Berger, F.G.** and H. Baumann. 1984. Alteration of Tissue-Specific Gene Expression During Evolution of *Mus*. *J. Cell Biol.* **99**:143a.
- (4.) **Berger, F.G.** 1985. A Molecular Geneticist's View of Cancer Chemotherapy. *Organ Systems Newsletter* **1**:7-8, NCI, Bethesda.
- (5.) Berger, S.H. and **F.G. Berger**. 1985. Thymidylate Synthase (TS): Gene Amplification in a Human Cell Line and Structural Gene Variations in Human Tumors. *Proc. Am. Assoc. Can. Res.* **26**:245.
- (6.) Berger, S.H., J. Clark, D. Kabus, and **F.G. Berger**. 1986. Thymidylate Synthase: Enzyme, mRNA, and Structural Gene Variation in Human Colonic Cell Lines and Tumors. *Proc. Am. Assoc. Can. Res.* **27**:298.
- (7.) Clark, J.L., S.H. Berger, A. Mittelman, and **F.G. Berger**. 1987. Thymidylate synthase gene expression in human colonic tumor cell lines and colorectal carcinoma. *Proc. Inst. Med. Chicago.* **40**:30.
- (8.) Schonfeld, C., C. Porter, and **F.G. Berger**. 1987. Evolution of steroid-modulated ornithine decarboxylase expression in the mouse kidney. 15th Molecular and Biochemical Genetics Workshop, St. Croix, U.S.V.I.
- (9.) Rheaume, C., J. Latimer, H. Baumann, and **F.G. Berger**. 1987. Species- and tissue-specific regulation of alpha-1-antitrypsin gene transcription. 15th Molecular and Biochemical Genetics Workshop, St. Croix, U.S.V.I.
- (10.) Berger, S.H., K.W. Barbour, and **F.G. Berger**. 1988. A Variant Form of Thymidylate Synthase Confers Increased Resistance to 5-fluorodeoxyuridine in Human Colonic Tumor Cells. *Proc. Am. Assoc. Can. Res.* **29**:290.
- (11.) **Berger, F.G.** 1989. Chromosomes in the Courtroom. *Legal Times* **12**:19-20.
- (12.) Barbour, K.W., S.H. Berger, and **F.G. Berger**. 1990. Primary structure of a naturally occurring genetic variant of human thymidylate synthase. *Proc. Am. Assoc. Can. Res.* **31**:423.
- (13.) **Berger, F.G.**, K.W. Barbour, C.T. Hughey, and S.H. Berger. 1991. Molecular markers for predicting cellular response to 5-fluoropyrimidines. *Proc. Am. Assoc. Can. Res.* **32**:413.
- (14.) Reilly, R.T., K.W. Barbour, R.B. Dunlap, and **F.G. Berger**. 1994. Rapid kinetic analysis of 5-fluorodeoxyuridylate binding in naturally-occurring mutant form of human thymidylate synthase: Comparison to the wild type enzyme. *FASEB J.* **8**:1286.
- (15.) Kitchens, M.E. and **F.G. Berger**. 1997. Relationships between mismatch repair defects and expression of thymidylate synthase in fluoropyrimidine-sensitive and -resistant colon tumor cell lines. *Proc. Am. Assoc. Cancer Res.* **38**: 614.
- (16.) Kitchens, M.E., Z. Rafique, H.T. Spencer, and **F.G. Berger**. 1999. Ligand-mediated induction of thymidylate synthase occurs by enzyme stabilization. *Proc. Amer. Assoc. Can. Res.* **40**:400.
- (17.) **Berger, F.G.** 2005. Polyamine metabolism and modulation of intestinal tumorigenesis in the *Apc^{Min/+}* mouse. Gordon Research Conference on Polyamines. New London, CT, June 12-17.
- (18.) Peña, M.M.O., Davis, C., Koli, S., Tucker, J.T, Baudino, T., Price, R., Borg, T., and **Berger, F.G.** 2005. Effect of transplantation of drug resistant hematopoietic stem cells on tumor response to chemotherapy in *Apc^{Min/+}* Mice. Keystone Symposium on The Role of

Curriculum Vitae: F.G. Berger

Microenvironment in Tumor Induction and Progression. Banff, Alberta, Canada, February 5-10.

- (19.) Peña, M.M.O., Davis, C., Koli, S., Tucker, J.T, Baudino, T., Price, R., Borg, T., and **Berger, F.G.** 2005. The role of the tumor microenvironment in intestinal tumor response to chemotherapy using thymidylate synthase inhibitors in the *Apc^{Min/+}* mouse. AACR Special Conference in Cancer Research on Colorectal Cancer: Molecular Pathways and Therapies. Dana Point, CA, October 19-23.
- (20.) **Berger, F.G.**, D.L. Kramer, and C.W. Porter. 2006. Polyamine metabolism and tumorigenesis in the *Apc^{Min/+}* mouse. Health implications of dietary amines. Biochemical Society Focused Conference, Aberdeen, U.K., October 19-21.
- (21.) Clinton, S.A., K.W. Barbour, U. Ozer, and **F.G. Berger.** 2014. NRF2 modulates sensitivity to thymidylate synthase inhibitors in colon cancer cells. In: *Proceedings of the 105th Annual Meeting of the American Association for Cancer Research*; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; 2014. Abstract nr 493.
- (22.) Caldwell, R., Eberth, J., Thibault, A., Seabrook, M., and **Berger, F.** 2015. A High-Quality Colonoscopy Screening Program for the Uninsured and Medically Underserved in South Carolina. The American College of Gastroenterology Annual Meeting, Honolulu, HI, October 16-21.

CURRENT EXTRAMURAL GRANT SUPPORT:

National Institutes of Health (P30 GM10336-10): *Center for Colon Cancer Research.* \$747,619 direct costs for period 08/01/15 - 07/31/16; total funding period 09/09/13-07/31/18.

Role: PI

BlueCross/BlueShield of South Carolina Foundation (No. 2016-11): *The South Carolina Colon Cancer Prevention Network.* \$262,000 direct costs for period 06/01/2016 – 05/31/18.

Role: PI

Duke Endowment (No. 6420-SP): *South Carolina Colon Cancer Prevention Network.* \$437,204 direct costs for period 06/04/2015 – 06/03/2017.

Role: PI

State of South Carolina (Budget Proviso 118.16): *Colon Cancer Prevention Network.* \$500,000, FY 2016-17.

Role: PI

Centers for Disease Control (5 NU58DP006137-02-00): *Colorectal Cancer Screening Program in South Carolina.* \$626,343 direct costs for period 06/30/2016 – 06/29/2017; total funding period 06/30/2015 – 06/29/2020.

Role: PI; Dr. Heather Brandt, Co-PI

DEPARTMENT SERVICE:

Graduate Studies Committee, 1986-89; Belle Camp Symposium Committee, 1987-89; Information Resources Committee, 1987-89; Editor, *Biospheres* Newsletter, 1987-89; Seminar Committee, 1987-present; Search Committees, 1987, 1990, 1992; Search Committee Chairman, 1992; Internal Review Committee, 1988-89; Associate Professor Peer Review Committee, 1991-93; Chairman, Associate Professor Peer Review Committee, 1992-93; Chair's Advisory Committee, 1991-1996; Chairman, Molecular, Cell, and Developmental Biology Group, 1993-1996; Faculty Senator, 1993-1996; *Peromyscus* Stock Center Committee, 1992-1996; Department Chair, 1996-2002; Peer Review Committee for Associate Professors, 2005- 2011.

COLLEGE AND UNIVERSITY SERVICE:

Animal Care Committee, 1986-89; ACS Institutional Grant Review Committee, 1986-89; Research and Productive Scholarship Committee, 1987-89; Director, Institute of Biological Research and Technology, 1987-90; EPSCoR Committee, 1989; Space Committee, 1992-93; Venture Fund Review Committee, 1993; Chairman, Venture Fund Review Committee, 1993-1994; Admissions Committee, 1993-96; Executive Management Committee, South Carolina Cancer Center, 1998-present; Chair, Review Committee for Dean of the Medical School, 2000; Russell & Educational Foundation Research Awards Committee, 2000-2002; Chair, Russell & Educational Foundation Research Awards Committee, 2002; Director, Center for Colon Cancer Research, 2002-present; Biomedical Research Infrastructure Committee, 2003-2005; Dean's Academic Planning Council, 2005-2013; Review panel for provost REC Grants, 2014.

NATIONAL/INTERNATIONAL SERVICE:

NIH Panel: NIDDK Kidney/Urology Centers, 1987; NIH Study Section: Mammalian Genetics (ad hoc member), 1987, 1989; NSF Biological Centers Review Panel, 1987; NIH Site Visit: Mayo Clinic and Foundation, 1988; NIH Site Visit: Baylor College of Medicine, 1988; Organizer, USC Symposium on Biotechnology in Society, 1988; NIH Study Section: Biological Sciences (ad hoc member), 1989-90; Chairman, 17th Molecular and Biochemical Genetics Workshop, Bar Harbor, Maine, 1991; Member, Biological Sciences Study Section, NIH, 1990-94; NIH Site Visit: Penn State University Medical School at Hershey, Hershey, PA, 1993; Reserve member, Biological Sciences Study Section, NIH, 1994-1996; NIH Site Visit: Mayo Clinic and Research Foundation, Rochester, MN, 1995; NIH Site Visit: Penn State University Medical School at Hershey, Hershey, PA, 1996; Co-organizer, Keystone Conference on Functional Evolution of Macromolecules, Santa Fe, NM, 1997; NIH Technical Evaluation Panel: Evaluation of Chemopreventive Agents, 1999; NIH Small Business Incentive Research Program Study Section, 2000-2002; NIH Special Emphasis Review Panel: Experimental Therapeutics, 2003; Science Foundation of Ireland: Women in Science and Engineering Research Program Reviewer, 2006-2007; Chairman, Colorectal Cancer Working Group, SC Cancer Alliance, 2007-2010; Science Foundation of Arizona: Research Incentive Program Reviewer, 2008; National Research Foundation of the United Arab Emirates: Reviewer, 2008; Board of Directors, SC Cancer Alliance, 2009-present; Steering Committee, National Colorectal Cancer Roundtable, 2012-present; Editorial Board, *Colorectal Cancer*, 2011-present.

Curriculum Vitae: F.G. Berger

STUDENTS:

Lynn Celenza, M.S. 1982; Julie Tseng-Crank, Ph.D. 1986; Jean Latimer, Ph.D. 1989 (co-advisor with H. Baumann); David Kass, Ph.D. 1990 (co-advisor with W. Dawson); Myung-Chull Rhee, Ph.D. 1991; Dwight Dimaculangan, Ph.D. 1992; Gregg Johannes, Ph.D. 1992; Richard Goodwin, Ph. D. 1996; Nandita Singh, Ph.D. 1997; Maria Kitchens, Ph.D. 1999; Jody Tucker, Ph.D. 2004; John Murphy, Ph.D. 2006; Kenneth White, Ph.D. 2008; Sandra Melo, Ph.D. 2009; Ufuk Ozer, Ph.D. 2013; Sarah Clinton, 2012-present.

POSTDOCTORAL AND SENIOR FELLOWS:

Dr. John Clark, 1984-85; Dr. Anuradha Chaudhuri, 1986-89; Dr. Farrokh Asadi, 1990-94; Dr. Gregg Johannes, 1992-93; Dr. Margaret Liu, 1993-95; Dr. Tom Borg, Visiting Fellow, 1993-1995; Dr. R. Todd Reilly, 1994-96; Dr. Bhuvana Parameswaran, 1995-97; Dr. Maria Kitchens, 1999-2001; Dr. Tina Forsthoefel, 1994-2003; Dr. Marj Peña, 2000-2006.

UNDERGRADUATE COURSES TAUGHT:

1989-1994	BIOLOGY 111, Biological Principles (100-120 students) SCCC 101, Principles of Biology (20-25 students in the South Carolina Honors College)
2002	BIOLOGY 645, Senior Seminar (12 students)
2004	BIOLOGY 599, Hallmarks of Cancer (25 students)
2005	BIOLOGY 599, Hallmarks of Cancer (31 students)
2006	BIOLOGY 610, Hallmarks of Cancer (35 students)
2007	BIOLOGY 610, Hallmarks of Cancer (32 students)

GRADUATE COURSES TAUGHT:

1986-1990	BIOLOGY 712, Gene Expression (9-12 students)
1987-1990	BIOLOGY 665, Human Biochemical Genetics (10-17 students)